S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Are These 3 Video Game Stocks Now In Play?
Biden's Plan to Confiscate Your Cash? (Ad)
Agilent Technologies Proves Its Worth VS Illumina 
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Lowe’s Stands Out Amid Q2 Retail Reports 
Egypt's central bank governor resigns as economic woes mount
Stocks slip on Wall Street, erasing weekly gains for S&P 500
3rd Massive Dollar Upheaval Has Started (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Are These 3 Video Game Stocks Now In Play?
Biden's Plan to Confiscate Your Cash? (Ad)
Agilent Technologies Proves Its Worth VS Illumina 
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Lowe’s Stands Out Amid Q2 Retail Reports 
Egypt's central bank governor resigns as economic woes mount
Stocks slip on Wall Street, erasing weekly gains for S&P 500
3rd Massive Dollar Upheaval Has Started (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Are These 3 Video Game Stocks Now In Play?
Biden's Plan to Confiscate Your Cash? (Ad)
Agilent Technologies Proves Its Worth VS Illumina 
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Lowe’s Stands Out Amid Q2 Retail Reports 
Egypt's central bank governor resigns as economic woes mount
Stocks slip on Wall Street, erasing weekly gains for S&P 500
3rd Massive Dollar Upheaval Has Started (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Are These 3 Video Game Stocks Now In Play?
Biden's Plan to Confiscate Your Cash? (Ad)
Agilent Technologies Proves Its Worth VS Illumina 
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Lowe’s Stands Out Amid Q2 Retail Reports 
Egypt's central bank governor resigns as economic woes mount
Stocks slip on Wall Street, erasing weekly gains for S&P 500
3rd Massive Dollar Upheaval Has Started (Ad)
NASDAQ:OCGN

Ocugen - OCGN Stock Forecast, Price & News

$2.67
-0.10 (-3.61%)
(As of 08/17/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.67
$2.77
50-Day Range
$1.94
$3.10
52-Week Range
$1.67
$17.65
Volume
3.98 million shs
Average Volume
8.94 million shs
Market Capitalization
$578.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.40

Ocugen MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
177.2% Upside
$7.40 Price Target
Short Interest
Bearish
25.72% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.22mentions of Ocugen in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$549,495 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.71 out of 5 stars

Medical Sector

988th out of 1,122 stocks

Biological Products, Except Diagnostic Industry

157th out of 178 stocks

OCGN stock logo

About Ocugen (NASDAQ:OCGN) Stock

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

Ocugen Stock Down 3.8 %

Shares of NASDAQ:OCGN opened at $2.77 on Wednesday. Ocugen has a 1 year low of $1.67 and a 1 year high of $17.65. The firm's 50-day moving average is $2.52 and its 200-day moving average is $2.77. The company has a current ratio of 11.86, a quick ratio of 11.86 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $599.90 million, a PE ratio of -9.23 and a beta of 4.24.

Analyst Ratings Changes

Several equities analysts recently commented on OCGN shares. Chardan Capital cut their target price on Ocugen from $4.00 to $3.50 and set a "neutral" rating for the company in a research report on Monday, May 9th. Roth Capital reaffirmed a "buy" rating and set a $8.00 price objective on shares of Ocugen in a report on Wednesday, June 15th. HC Wainwright reduced their target price on Ocugen from $7.00 to $6.00 and set a "buy" rating on the stock in a report on Monday. Finally, Cantor Fitzgerald started coverage on Ocugen in a report on Thursday, June 2nd. They set an "overweight" rating and a $4.50 price target for the company. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, Ocugen currently has an average rating of "Moderate Buy" and a consensus target price of $7.40.

Insider Transactions at Ocugen

In related news, Director Kirsten Castillo sold 42,000 shares of the company's stock in a transaction dated Thursday, August 11th. The stock was sold at an average price of $2.91, for a total value of $122,220.00. Following the completion of the sale, the director now owns 50,000 shares in the company, valued at $145,500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Ocugen news, CEO Shankar Musunuri sold 150,000 shares of the business's stock in a transaction dated Thursday, July 14th. The shares were sold at an average price of $2.72, for a total transaction of $408,000.00. Following the sale, the chief executive officer now directly owns 752,540 shares of the company's stock, valued at approximately $2,046,908.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Kirsten Castillo sold 42,000 shares of the firm's stock in a transaction dated Thursday, August 11th. The shares were sold at an average price of $2.91, for a total value of $122,220.00. Following the completion of the transaction, the director now owns 50,000 shares of the company's stock, valued at approximately $145,500. The disclosure for this sale can be found here. Insiders have sold 199,500 shares of company stock worth $549,495 in the last three months. Insiders own 2.81% of the company's stock.

Receive OCGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocugen and its competitors with MarketBeat's FREE daily newsletter.

OCGN Stock News Headlines

Ocugen (NASDAQ:OCGN) Price Target Cut to $6.00
Here's How This Beaten-Down Stock Could 10X by 2024
1 Robinhood Stock to Avoid Right Now
Ocugen, Inc. (OCGN) Q2 2022 Earnings Call Transcript
Form 10-Q Ocugen, Inc. For: Jun 30 - StreetInsider.com
Ocugen Q2 Preview: Rebound Quarter Inbound?
Ocugen: Q2 Earnings Snapshot
Why Ocugen Is Climbing Today
See More Headlines
Receive OCGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocugen and its competitors with MarketBeat's FREE daily newsletter.

OCGN Company Calendar

Last Earnings
11/09/2021
Today
8/17/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OCGN
Employees
56
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.40
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$3.50
Forecasted Upside/Downside
+177.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-58,370,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$42.62 million
Book Value
$0.53 per share

Miscellaneous

Free Float
210,480,000
Market Cap
$578.23 million
Optionable
Not Optionable
Beta
4.24

Key Executives

  • Dr. Shankar Musunuri M.B.A. (Age 58)
    MBA, Ph.D., Co-Founder, Chairman & CEO
    Comp: $845.2k
  • Dr. Uday B. Kompella Ph.D. (Age 55)
    Co-founder & Independent Director
    Comp: $44k
  • Dr. Vijay Tammara Ph.D. (Age 62)
    Sr. VP of Regulatory & Quality
    Comp: $490.92k
  • Ms. Jessica Crespo CPA (Age 45)
    CPA, Chief Accounting Officer, Sr. VP of Fin. and VP of Corp. Controller & Treasurer
  • Mr. J. P. Gabriel
    Sr. VP of Technical Operations
  • Mr. Ken Inchausti
    Head of Investor Relations & Communications
  • Ms. Zara Gaudioso
    AVP, Head of HR & Chief of Staff
  • Dr. Arun Upadhyay Ph.D.
    Sr. VP of R&D
  • Dr. Bruce D. Forrest B.S. (Age 59)
    M.B.A., M.D., Acting Chief Medical Officer & Vaccine Scientific Advisory Board Member
  • Mr. Michael Shine
    Sr. VP of Commercial













OCGN Stock - Frequently Asked Questions

Should I buy or sell Ocugen stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ocugen in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OCGN shares.
View OCGN analyst ratings
or view top-rated stocks.

What is Ocugen's stock price forecast for 2022?

5 Wall Street research analysts have issued 1-year price objectives for Ocugen's shares. Their OCGN share price forecasts range from $3.50 to $15.00. On average, they predict the company's stock price to reach $7.40 in the next twelve months. This suggests a possible upside of 177.2% from the stock's current price.
View analysts price targets for OCGN
or view top-rated stocks among Wall Street analysts.

How have OCGN shares performed in 2022?

Ocugen's stock was trading at $4.55 at the start of the year. Since then, OCGN stock has decreased by 41.3% and is now trading at $2.67.
View the best growth stocks for 2022 here
.

When is Ocugen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our OCGN earnings forecast
.

How were Ocugen's earnings last quarter?

Ocugen, Inc. (NASDAQ:OCGN) released its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by $0.01. During the same period in the prior year, the business posted ($0.07) EPS.

What other stocks do shareholders of Ocugen own?
What is Ocugen's stock symbol?

Ocugen trades on the NASDAQ under the ticker symbol "OCGN."

Who are Ocugen's major shareholders?

Ocugen's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include State Street Corp (14.14%), JPMorgan Chase & Co. (1.52%), Northern Trust Corp (0.94%), Rafferty Asset Management LLC (0.64%), UBS Group AG (0.40%) and Renaissance Technologies LLC (0.29%). Insiders that own company stock include Christopher Dold, Daniel Purefoy, Howard C Draft, Junge Zhang, Kirsten Castillo, Manish Potti, Prabhavathi Fernandes, Ramesh Kumar, Sanjay Subramanian, Shankar Musunuri, Uday Kompella and Vijay Tammara.
View institutional ownership trends
.

How do I buy shares of Ocugen?

Shares of OCGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ocugen's stock price today?

One share of OCGN stock can currently be purchased for approximately $2.67.

How much money does Ocugen make?

Ocugen (NASDAQ:OCGN) has a market capitalization of $578.23 million and generates $42.62 million in revenue each year. The company earns $-58,370,000.00 in net income (profit) each year or ($0.30) on an earnings per share basis.

How can I contact Ocugen?

Ocugen's mailing address is 5 GREAT VALLEY PARKWAY V, MALVERN PA, 19355. The official website for the company is ocugen.com. The company can be reached via phone at (484) 328-4701, via email at ir@ocugen.com, or via fax at 781-547-4452.

This page (NASDAQ:OCGN) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.